

# Nicolas C Kahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4982903/publications.pdf>

Version: 2024-02-01

36  
papers

2,554  
citations

623734

14  
h-index

526287

27  
g-index

39  
all docs

39  
docs citations

39  
times ranked

4529  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>SARS</scp> â€CoVâ€2 receptor <scp>ACE</scp> 2 and <scp>TMPRSS</scp> 2 are primarily expressed in bronchial transient secretory cells. EMBO Journal, 2020, 39, e105114.	7.8	812
2	SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO Journal, 0, , e105114.	7.8	340
3	Combined Endoscopic-Endobronchial Ultrasound-Guided Fine-Needle Aspiration of Mediastinal Lymph Nodes Through a Single Bronchoscope in 150 Patients With Suspected Lung Cancer. Chest, 2010, 138, 790-794.	0.8	260
4	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 476-486.	10.7	254
5	The therapy of idiopathic pulmonary fibrosis: what is next?. European Respiratory Review, 2019, 28, 190021.	7.1	157
6	LungPointâ€™A New Approach to Peripheral Lesions. Journal of Thoracic Oncology, 2010, 5, 1559-1563.	1.1	111
7	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. European Respiratory Journal, 2020, 56, 1902279.	6.7	102
8	Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases. Respiration, 2014, 88, 199-207.	2.6	98
9	Hypoxic Epithelial Necrosis Triggers Neutrophilic Inflammation via IL-1 Receptor Signaling in Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 902-913.	5.6	78
10	Fibroblast Activation Proteinâ€™Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. Journal of Nuclear Medicine, 2022, 63, 127-133.	5.0	72
11	Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection. European Respiratory Journal, 2021, 57, 2003002.	6.7	37
12	â€™Heat and Destroyâ€™™: Bronchoscopic-Guided Therapy of Peripheral Lung Lesions. Respiration, 2010, 79, 265-273.	2.6	24
13	Optical coherence tomography detects structural abnormalities of the nasal mucosa in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 216-222.	0.7	19
14	Early Detection of Lung Cancer by Molecular Markers in Endobronchial Epithelial-Lining Fluid. Journal of Thoracic Oncology, 2012, 7, 1001-1008.	1.1	16
15	C-proSP-B: A Possible Biomarker for Pulmonary Diseases?. Respiration, 2018, 96, 117-126.	2.6	15
16	Evolution and treatment of idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104025.	1.9	15
17	Gene expression analysis of endobronchial epithelial lining fluid in the evaluation of indeterminate pulmonary nodules. Journal of Thoracic and Cardiovascular Surgery, 2009, 138, 474-479.	0.8	14
18	Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. Oncotarget, 2016, 7, 71285-71297.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Profibrotic epithelial TGF- $\beta$ 1 signaling involves NOX4-mitochondria cross talk and redox-mediated activation of the tyrosine kinase FYN. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L356-L367.	2.9	12
20	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. Cancers, 2018, 10, 486.	3.7	11
21	Blood-sampling collection prior to surgery may have a significant influence upon biomarker concentrations measured. Clinical Proteomics, 2015, 12, 19.	2.1	10
22	Determinants of health-related quality of life decline in interstitial lung disease. Health and Quality of Life Outcomes, 2020, 18, 334.	2.4	9
23	A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung Diseases. Respiration, 2020, 99, 119-124.	2.6	8
24	Establishment of a Tissue-Mimicking Surrogate for Pulmonary Lesions to Improve the Development of RFA Instruments and Algorithms. Biomedicines, 2022, 10, 1100.	3.2	2
25	Clinical highlights from the 2016 European Respiratory Society International Congress. ERJ Open Research, 2017, 3, 00147-2016.	2.6	1
26	European Respiratory Society International Congress 2017: highlights from the Clinical Assembly. ERJ Open Research, 2018, 4, 00134-2017.	2.6	1
27	New kids on the block in the ECMC and opportunities for early career members in 2018. Breathe, 2018, 14, 55-57.	1.3	1
28	European Respiratory Society International Congress, Paris, 2018: highlights from the Clinical Assembly. ERJ Open Research, 2019, 5, 00176-2018.	2.6	1
29	Juniors'™ voice at the ERS International Congress, Amsterdam 2015. Breathe, 2015, 11, 303-305.	1.3	0
30	Early Career Members at the ERS International Congress London 2016. Breathe, 2016, 12, 364-368.	1.3	0
31	LSC 2016: from system approaches in lung disease to getting the job you want. Breathe, 2016, 12, 169-173.	1.3	0
32	Preview of highlighted presentations from the European Respiratory Society's™ clinical assembly. Journal of Thoracic Disease, 2018, 10, S3034-S3042.	1.4	0
33	Anti-DSF70 zur Differenzierung der Genese von interstitiellen Lungenerkrankungen. Karger Kompass Autoimmun, 2019, , 23-24.	0.0	0
34	Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease: In Search for Evidence-Based Medicine. Respiration, 2020, 99, 930-931.	2.6	0
35	Anti-DSF70 zur Differenzierung der Genese von interstitiellen Lungenerkrankungen. Karger Kompass Pneumologie, 2020, 8, 78-79.	0.0	0
36	ERS International Congress 2017: a peek of outstanding abstracts from the clinical assembly. Journal of Thoracic Disease, 2017, 9, S1526-S1531.	1.4	0